A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Allergan
- 22 Jun 2018 Planned End Date changed from 8 Jun 2021 to 18 Jan 2020.
- 22 Jun 2018 Planned primary completion date changed from 8 Jun 2021 to 18 Jan 2020.
- 15 Mar 2018 Status changed from not yet recruiting to recruiting.